REV-MED
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
REV-MED - overview
Established
2009
Location
Seongnam, Gyeonggi, South Korea
Primary Industry
Biotechnology
About
Based in Seongnam, South Korea and founded in 2009, REV-MED Inc. is a biotech company that focuses on the development of therapeutic lasers and autologous biologic systems. In 2014, the company developed an autologous bone marrow-derived stem cell and nucleated cell concentration kit. In 2017, the company developed a high-capacity autologous bone marrow stem cell extractor.
In 2018, the company established the REV-MED Stem Cell Institute. In 2020, the company obtained EN ISO 13485 : 2018 and Hilthera 4. 0 CE certification. The company's main products include Tricell PRP, Tricell BMC, Hithera4.
0 and Duocell SVF Kit. TriCell PRP separates platelet-rich, yellow-brown layers from blood samples. The Hithera 4. 0 is a medical laser device that relieves pain caused by sports injuries by irradiating at a peak power of 1,200mJ (1064nm).
Current Investors
AJU IB Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.rev-med.co.kr
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
REV-MED - timeline of key events
REV-MED - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue (USD) | 4,375,114,048 | 5,892,327,561 | - | - | - |
| % Revenue Growth (YoY) | - | 34.7% | - | - | - |
| EBITDA (USD) | 1,463,873,342 | 1,329,376,539 | - | - | - |
| Operating Income (USD) | 1,353,269,674 | 1,136,961,010 | - | - | - |
| Operating Margin | 30.9% | 19.3% | - | - | - |
| % EBITDA Margin | 33.5% | 22.6% | - | - | - |
| NET Income (USD) | 1,622,825,687 | 960,327,733 | - | - | - |
| % Net Margin | 37.1% | 16.3% | - | - | - |
REV-MED - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.